Ulcerative Colitis Clinical Trials

Showing 6181-6200 of 9,572 trials

Reducing Errors In The Neonatal Intensive Care Unit

NCT04193839

This is a monocentric prospective pre and post-intervention study, aiming at analyzing the efficacy of the Computerized Provider Order Entry (CPOE) plus Bar Code Medication Administration (BCMA) as compared to paper order entry in reducing medication erros (MEs) in the Neonatal Intensive Care Unit (NICU)

Medication Errors and Other Product Use Errors and IssuesAdverse Drug Event

Fondazione Poliambulanza Istituto Ospedaliero100 participantsStarted Jan 2020

Brescia, Italy

COMPLETEDPhase 3

(CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis

NCT00679380

This will be a multicentre, randomised, double-blind, double-dummy, parallel group comparative study in patients with mild or moderate, active ulcerative colitis. The study will compare budesonide-MMX™ 6 mg and budesonide-MMX™ 9 mg tablets to placebo and to Entocort® 3 x 3 mg capsules, in four parallel groups of patients over an 8 week treatment period. After the screening visit, patients will enter a washout period of 2 days, then they will be randomised to the following four treatment groups: budesonide-MMX™ tablets (6 mg), budesonide-MMX™ tablets (9 mg), Entocort® capsules (3 x 3 mg) and placebo (tablets and capsules), all administered once a day after breakfast. Hence, each patient will receive, in the morning after breakfast, either one budesonide-MMX™ 6 mg or budesonide MMX™ 9 mg tablet and 3 placebo Entocort® matching capsules, or three Entocort® 3 mg capsules and one placebo budesonide-MMX™ matching tablet, or one placebo budesonide-MMX™ matching tablet and three placebo Entocort® matching capsules.

Ulcerative Colitis

Bausch Health Americas, Inc.514 participantsStarted Jun 2008

Sydney, New South Wales, Australia • Adelaide, Australia • Box Hill, Australia +68 more locations

Reducing Errors In The Neonatal Intensive Care Unit

(CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis

Related Searches

Utility of EUS-guided Microbiopsies in Pancreatic Cystic Lesions

An Emotion Regulation Intervention for Early Adolescent Risk Prevention

Evolution of Fatigue in Patients With Inflammatory Bowel Disease

Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma

Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders

Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in People With Insulin Receptor Mutations

The Role of Glucocorticoid Receptor SNPs in Receptor Function and Metabolic Disease

The Use of Oral Budesonide and Rectal Hydrocortisone for the Treatment of Active Ulcerative Colitis

Macrophage Phagocytosis in COPD

Endothelial Function Evaluation in Patients With PAOD Treated With Sulodexide + Conventional Treatment (CT) Vs CT Alone

Prognostic Value of the Urinary Nerve Growth Factor in the Patients With Benign Prostatic Hyperplasia

Comparison Between Invasive Pressure Flow Study and Non-invasive Penile Cuff Test

High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase After Mastectomy

The Study for the Reliability and Validity of Incremental Shuttle Walking Test for COPD Patients in Korea

Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity

CATS Tonometer IOP Reduction Latanoprost Verses Timolol

CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma

A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients